ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT)

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. Schedule 13G/A shows ARK Investment Management LLC and Catherine D. Wood report beneficial ownership of 2,947,556 shares of Common Stock, representing 10.37% of the class. ARK holds sole voting and dispositive power over 2,947,556 shares; Catherine D. Wood holds shared voting and dispositive power over the same amount. Signatures dated 05/07/2026 appear on the amendment.

Key Figures

Shares beneficially owned: 2,947,556 shares Percent of class: 10.37% CUSIP: 03969T109 +1 more

4 metrics

Shares beneficially owned 2,947,556 shares Amount reported by ARK and Catherine D. Wood

Percent of class 10.37% Percentage of common stock reported beneficially owned

CUSIP 03969T109 Identifier for Common Stock class

Signature date 05/07/2026 Date signatures were provided on the amendment

Key Terms

Schedule 13G/A, beneficially owned, sole voting power, shared dispositive power

4 terms

Schedule 13G/A regulatory

"Amendment No. 10 ) Arcturus Therapeutics Holdings Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: ARK and Catherine D. Wood: 2,947,556"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 2,947,556.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"Shared Dispositive Power 2,947,556.00"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 10)

Arcturus Therapeutics Holdings Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03969T109

(CUSIP Number)

04/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03969T109

1

Names of Reporting Persons

ARK Investment Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,947,556.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,947,556.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,947,556.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.37 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 03969T109

1

Names of Reporting Persons

Catherine D. Wood

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,947,556.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,947,556.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,947,556.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.37 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Arcturus Therapeutics Holdings Inc.
(b)	Address of issuer's principal executive offices: 10285 Science Center Drive, San Diego , CA 92121
Item 2.
(a)	Name of person filing: (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
(b)	Address or principal business office or, if none, residence: ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
(c)	Citizenship: (i) ARK: Delaware (ii) Catherine D. Wood: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 03969T109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: ARK and Catherine D. Wood: 2,947,556
(b)	Percent of class: ARK and Catherine D. Wood: 10.37
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (i) ARK: 2,947,556 (ii) Catherine D. Wood: 0
	(ii) Shared power to vote or to direct the vote: (i) ARK: 0 (ii) Catherine D. Wood: 2,947,556
	(iii) Sole power to dispose or to direct the disposition of: (i) ARK: 2,947,556 (ii) Catherine D. Wood: 0
	(iv) Shared power to dispose or to direct the disposition of: (i) ARK: 0 (ii) Catherine D. Wood: 2,947,556
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. No client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Genomic Revolution ETF, a series of a Delaware statutory trust.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARK Investment Management LLC

Signature:	/s/ Kellen Carter
Name/Title:	Kellen Carter, Chief Compliance Officer
Date:	05/07/2026

Catherine D. Wood

Signature:	/s/ Catherine D. Wood
Name/Title:	Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:	05/07/2026

FAQ

What stake does ARK hold in Arcturus Therapeutics (ARCT)?

ARK Investment Management LLC reports beneficial ownership of 2,947,556 shares, equal to 10.37% of Arcturus Therapeutics' common stock. The filing states ARK has sole voting and sole dispositive power over those shares.

What role does Catherine D. Wood have in the ARCT holdings?

Catherine D. Wood is listed as a reporting person with 2,947,556 shares reported as beneficially owned and 10.37% of the class; she is shown with shared voting and shared dispositive power over those shares.

When was the Schedule 13G/A for ARCT signed?

The amendment is signed by Kellen Carter and Catherine D. Wood with signature dates of 05/07/2026. The cover lists the amendment date as 04/30/2026 and the filing identifies the CUSIP 03969T109.

Does ARK report any client with over 5% ownership in ARCT?

The filing states no client of ARK currently has an interest in excess of 5% except ARK Genomic Revolution ETF, a series of a Delaware statutory trust, which is identified in the disclosure.